Skip to main content

Sotyktu Dosage

Generic name: DEUCRAVACITINIB 6mg
Dosage form: tablet, film coated
Drug class: Multikinase inhibitors

Medically reviewed by Last updated on Sep 9, 2022.

Recommended Evaluations and Immunizations Prior to Treatment Initiation

Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU. If positive, start treatment for TB prior to SOTYKTU use [see Warnings and Precautions (5.3)].

Update immunizations according to current immunization guidelines [see Warnings and Precautions (5.7)].

Recommended Dosage

The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.

Do not crush, cut, or chew the tablets.

Recommended Dosage in Patients with Hepatic Impairment

SOTYKTU is not recommended in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

No dosage adjustment is needed for patients with mild to moderate hepatic impairment.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.